Journal article icon

Journal article

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial

Abstract:

BACKGROUND:There is an urgent need for an effective tuberculosis (TB) vaccine. Heterologous prime-boost regimens induce potent cellular immunity. MVA85A is a candidate TB vaccine. This phase I clinical trial was designed to evaluate whether alternating aerosol and intradermal vaccination routes would boost cellular immunity to the Mycobacterium tuberculosis antigen 85A (Ag85A). METHODS AND FINDINGS:Between December 2013 and January 2016, 36 bacille Calmette-Guérin-vaccinated, healthy UK adult...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1371/journal.pmed.1002790

Authors


More by this author
Role:
Author
ORCID:
0000-0002-1494-2440
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDM
Sub department:
Jenner Institute
Role:
Author
Publisher:
Public Library of Science
Journal:
PLoS Medicine More from this journal
Volume:
16
Issue:
4
Pages:
e1002790
Publication date:
2019-04-30
Acceptance date:
2019-03-26
DOI:
EISSN:
1549-1676
ISSN:
1549-1277
Pmid:
31039172
Language:
English
Keywords:
Pubs id:
pubs:995629
UUID:
uuid:d0fd4c71-8b3c-4b81-8a29-6f5b029f5216
Local pid:
pubs:995629
Source identifiers:
995629
Deposit date:
2019-05-09

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP